When you enroll through our links, we may earn a small commission—at no extra cost to you. This helps keep our platform free and inspires us to add more value.
Molecular Tumor Board 2021-22
Master the Skills of Tomorrow with Coursera! From AI and Blockchain to Public Speaking and Psychology, Explore Courses Tailored for Your Success.
This Course Includes
coursera
0 (0 reviews )
Flexible schedule 
spanish
Online - Self Paced
course
Universitat de Barcelona
About Molecular Tumor Board 2021-22
Se trata de un curso que nace a raíz de una de las sesiones formativas que realiza cada 15 días el Servicio de Oncología Médica del Hospital Clínic de Barcelona (HCB). En este curso se presentan casos clínicos simulando un MTB de tumores sólidos, con un objetivo principal, mejorar el conocimiento específico del impacto clínico del perfil molecular en tumores sólidos. Está destinado a médicos oncólogos y a estudiantes y profesionales vinculados a la oncología médica. Cada seminario que conforma el curso lo presenta un profesional de una patología diferente del Servicio de Oncología Médica del HCB. El curso está ACREDITADO por el "Consell Català de la Formació Continuada de les Professions Sanitàries (CCFCPS)" con 4,2 créditos.
What You Will Learn?
- Thoracic Tumor - Somatic and germinal, both are deletions by Dr. Lucio Ghiglione Learning from failures by Dr. Helena Oliveres Selecting patients for PARPis in Ovarian Cancer: ¿How can we best indentify them? by Dr. Lydia Gaba Intrinsic Subtypes and Therapeutic Decision-Making in HR+HER2-negative Metastatic Breast Cancer by Dr. Francesco Schettini DNA repair and clinical evolutiol of metastatic prostate cancer by Dr. Caterina Aversa Change in phenotype and somatic BRCA1 mutation in a patient with advanced breast cancer by Dr. Barbara Adamo Done right, went wrong by Dr. Victor Albarran Can be guided treatment strategy without somatic molecular profile? by Dr. Juan Carlos Laguna Precision medicine in non-melanoma skin cancer by Dr. Elia Segui Unexpected response in a rare tumor by Dr. David Pesantez Mejorando la supervivencia en cáncer de mama mestatásico by Dr. Maria Vidal Beyond BRCA1 and 2 in ovarian cancer by Dr. Adela Rodríguez "Not everything is what it seems to be”... The correct interpretation of tumor molecular studies and the importance of a multidisciplinar approach Dr. Belen Pastor Never too late to think twice by Dr. Marta García de Herreros Do we have predictive biomarkers in urothelial carcinoma (UC) beyond FGFR alterations? by Dr. Oscar Reig Agnostic Biomarker in solid tumors by Dr. Laura Angelats What acral melanoma hides by Dr. Roberto Martín Molecular Family by Dr. Roxana Reyes Is there any rol for precision medicine in rare pacreatic cancer? by Dr. Francis Espósito Beyond the classical EGFR resistance mechanisms by Teresa Gorria Breast cancer: Beyond intrinsic subtypes by Raquel Gómez Intrahepatic cholangiocarcinoma: beyond chemotherapy by Dr. Iván Victoria Exploiting genomics in serous endometrial cancer by Lydia Gaba Beyond classical BRAF mutations in melanoma by Dr. Marta García de Herreros Can we talk about Precision Immuno-Oncology in HR+ HER2- Breast Cancer? by Elia Seguí Brain tumor by Estela Pineda.